JPMorgan lowered Sarepta Therapeutics, Inc. (SRPT) price target from $30 to $28 but maintained an “Overweight” rating due to a “valuation disconnect.” The company has FDA-approved treatments for Duchenne Muscular Dystrophy (DMD) and an approved gene therapy, Elevidys. Elevidys has full approval for ambulatory DMD patients, but discussions with the FDA are ongoing. Sarepta focuses on precision genetic medicines for rare diseases like DMD and limb-girdle muscular dystrophies. While SRPT shows potential, other AI stocks may offer greater upside. For more investment opportunities, check out semiconductor and fintech stocks. No disclosures.

Read more at Yahoo Finance: JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating